"VIDEO: What PCPs Need to Know About SGLT-2 Inhibitors in Patients With CKD"
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have been shown to be safe and effective second-line therapy in managing diabetes in multiple clinical trials, but clinicians need to consider their side effect profile when they are used in patients with chronic kidney disease. “Canagliflozin, dapagliflozin and empagliflozin have been shown in their respective clinical trials to reduce cardiovascular events and mortality, as well as improve kidney function, in patients with chronic kidney disease,” said Joseph Vassalotti, MD, associate clinical professor of nephrology at the Icahn School of Medicine at Mount Sinai. “These drugs have been associated with genitourinary infections, so that is a history or a risk that clinicians should consider.”
— Joseph A. Vassalotti, MD, Associate Clinical Professor, Medicine, Nephrology, Icahn School of Medicine at Mount Sinai